Clinical Trial: Upacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670156) titled 'Upacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations' on June 19.

Brief Summary: This study focuses on a genetic condition that affects the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) immune signaling pathway. A specific change in the DNA leads to overactivation of this pathway, which can result in immune dysregulation and related clinical symptoms.

Currently, five genetic mutations are known to cause these JAK-STAT pathway driven immune disorders: STAT1, STAT3, STAT5B, STAT6, and JAK1 (collectively referred to as JAK-STAT disorders). This study is a basket clinical trial, mea...